Drug Name	FDA Approval	Source (Partners)*	Type	Target	Approved and Investigational Indications
Alemtuzumab (Campath)	May 2001	BTG, West Conshohocken, PA (ILEX Oncology, Montville, NJ; Schering AG, Berlin, Germany)	Monoclonal antibody, humanized; anticancer, immunologic; multiple sclerosis treatment; immunosuppressant	CD52	Chronic lymphocytic and chronic myelogenous leukemia; multiple sclerosis, chronic progressive
Daclizumab (Zenapax)	March 2002	Protein Design Labs, Fremont, CA (Hoffmann-La Roche, Nutley, NJ)	Monoclonal IgG1 chimeric; immunosuppressant; antipsoriatic; antidiabetic; ophthalmologic; multiple sclerosis treatment	IL-2 receptor, CD25	Transplant rejection, general and bone marrow; uveitis; multiple sclerosis, relapsing-remitting and chronic progressive; cancer, leukemia, general; psoriasis; diabetes mellitus, type 1; asthma; ulcerative colitis
Rituximab (Rituxan)	November 1997	IDEC Pharmaceuticals, San Diego, CA (Genentech, South San Francisco, CA; Hoffmann-La Roche; Zen-yaku Kogyo, Tokyo, Japan)	Monoclonal IgG1 chimeric; anticancer, immunologic; antiarthritic, immunologic; immunosuppressant	CD20	Non-Hodgkin lymphoma, B-cell lymphoma, chronic lymphocytic leukemia; rheumatoid arthritis; thrombocytopenic purpura
Trastuzumab (Herceptin)	September 1998	Genentech (Hoffmann-La Roche; ImmunoGen, Cambridge, MA)	Monoclonal IgG1 humanized; anticancer, immunologic	p185neu	Cancer: breast, non-small cell of the lung, pancreas
Gemtuzumab (Mylotarg)	May 2000	Wyeth/AHP, Collegeville, PA	Monoclonal IgG4 humanized	CD33/cali-cheamicin	Acute myelogenous leukemia (patients older than 60 y)
Ibritumomab (Zevalin)	February 2002	IDEC Pharmaceuticals	Monoclonal IgG1 murine; anticancer	CD20/ yttrium 90	Low-grade lymphoma, follicular lymphoma, transformed non-Hodgkin lymphoma (relapsed or refractory)
Edrecolomab (Panorex)	January 1995†	GlaxoSmithKline, London, England	Monoclonal IgG2A murine; anticancer	Epithelial cell adhesion molecule	Cancer: colorectal

FDA, US Food and Drug Administration.

* Partners are companies that participated in drug development or that distribute the drug.

† Approved in Germany; not approved by the FDA.

Clinical Trial Status/Drug Name	Source	Features	Investigational Indications
Phase 3
Tositumomab (Bexxar)	Corixa, Seattle, WA	Anti-CD20 murine monoclonal antibody with iodine 131 conjugation	Non-Hodgkin lymphoma
CeaVac	Titan Pharmaceuticals, South San Francisco, CA	Anti-CEA murine monoclonal antibody; anticancer immunologic vaccine	Cancer: colorectal, non-small cell of the lung, breast, liver
Epratuzumab (LymphoCide)	Immunomedics, Morris Plains, NJ	Chimeric monoclonal antibody; anticancer immunologic; immunosuppressant	Non-Hodgkin lymphoma
Mitumomab	ImClone Systems, New York, NY	Murine monoclonal antibody; anticancer immunologic	Small cell cancer of the lung; melanoma
Bevacizumab (Avastin)	Genentech, South San Francisco, CA	Anti-VEGF humanized monoclonal antibody; anticancer immunologic; antidiabetic; ophthalmologic	Cancer: colorectal, breast, non-small cell of the lung; diabetic retinopathy
Cetuximab (C-225; Erbitux)	ImClone Systems	Anti-EGFR chimeric monoclonal antibody; anticancer immunologic	Cancer: head and neck, non-small cell of the lung, colorectal, breast, pancreas, prostate
Edrecolomab	Johnson & Johnson, New Brunswick, NJ	Murine monoclonal antibody; anticancer immunologic	Cancer: colorectal and breast
Lintuzumab (Zamyl)	Protein Design Labs, Fremont, CA	Chimeric monoclonal antibody; anticancer immunologic	Acute myelogenous leukemia; myelodysplastic syndrome
MDX-210	Medarex, Princeton, NJ; Immuno-Designed Molecules, Havana, Cuba	Bispecific chimeric monoclonal antibody; anti-HER-2/neu-anti-Fc gamma RI; anticancer immunologic	Cancer: ovarian, prostate, colorectal, renal, breast
IGN-101	Igeneon, Vienna, Austria	Murine monoclonal antibody; anticancer immunologic	Cancer: non-small cell of the lung, liver, colorectal, esophageal, stomach
Phase 2
MDX-010	Medarex	Humanized anti-HER-2 monoclonal antibody; anticancer immunologic; immunostimulant	Cancer: prostate, melanoma; infection, general
MAb, AME	Applied Molecular Evolution, San Diego, CA	Chimeric monoclonal antibody; anticancer immunologic; imaging agent; antiarthritic immunologic; ophthalmologic; cardiovascular	Cancer: sarcoma, colorectal; rheumatoid arthritis; psoriatic arthritis
ABX-EGF	Abgenix, Fremont, CA	Monoclonal antibody, human; anticancer immunologic	Cancer: renal, non-small cell of the lung, colorectal, prostate
EMD 72 000	Merck KGaA, Darmstadt, Germany	Chimeric monoclonal antibody; anticancer immunologic	Cancer: stomach, cervical, non-small cell of the lung, head and neck, ovarian
Apolizumab	Protein Design Labs	Chimeric monoclonal antibody; anticancer immunologic	Non-Hodgkin lymphoma; chronic lymphocytic leukemia
Labetuzumab	Immunomedics	Chimeric monoclonal antibody; immunoconjugate; anticancer immunologic	Cancer: colorectal, breast, small cell of the lung, ovarian, pancreas, thyroid, liver
ior-t1	Center of Molecular Immunology, Havana, Cuba	Murine monoclonal antibody; anticancer immunologic; antipsoriatic; antiarthritic immunologic	T-cell lymphoma; psoriasis; rheumatoid arthritis
MDX-220	Immuno-Designed Molecules	Chimeric monoclonal antibody; anticancer immunologic	Cancer: prostate, colorectal
MRA	Chugai Pharmaceutical, Tokyo, Japan	Chimeric monoclonal antibody; antiarthritic immunologic; anticancer immunologic; GI inflammatory and bowel disorders	Rheumatoid arthritis; cancer, myeloma; Crohn disease; Castleman disease
H-11 scFv	Viventia Biotech, Toronto, Canada	Humanized monoclonal antibody; anticancer immunologic	Non-Hodgkin lymphoma, melanoma
Oregovomab	AltaRex, Waltham, MA	Monoclonal antibody, murine; anticancer immunologic; immunoconjugate	Cancer: ovarian
huJ591 MAb, BZL	Millennium Pharmaceuticals, Cambridge, MA; BZL Biologics, Framingham, MA	Chimeric monoclonal antibody; anticancer immunologic	Cancer: prostate and general
Visilizumab	Protein Design Labs	Chimeric monoclonal antibody; immunosuppressant; anticancer immunologic; GI inflammatory and bowel disorders	Transplant rejection, bone marrow; cancer, T-cell lymphoma; ulcerative colitis; myelodysplastic syndrome; systemic lupus erythematosus
TriGem	Titan Pharmaceuticals	Murine monoclonal antibody; anticancer immunologic	Cancer: melanoma, small cell of the lung, brain
TriAb	Titan Pharmaceuticals	Murine monoclonal antibody; anticancer immunologic	Cancer: breast, non-small cell of the lung, colorectal
R3	Center of Molecular Immunology	Chimeric monoclonal antibody; anticancer immunologic; imaging agent; immunoconjugate	Cancer: head and neck; diagnosis of cancer
MT-201	Micromet, Munich, Germany	Humanized monoclonal antibody; anticancer immunologic	Cancer: prostate, colorectal, stomach, non-small cell of the lung
G-250, unconjugated	Johnson & Johnson	Chimeric monoclonal antibody; anticancer immunologic	Cancer: renal
ACA-125	CellControl Biomedical, Martinsried, Germany	Monoclonal antibody; anticancer immunologic	Cancer: ovarian
Onyvax-105	Onyvax, London, England	Monoclonal antibody; anticancer immunologic	Cancer: colorectal; sarcoma, general
Phase 1
CDP-860	Celltech, Slough, England	Humanized monoclonal antibody; anticancer immunologic; cardiovascular	Cancer: general; restenosis
BrevaRex MAb	AltaRex	Murine monoclonal antibody; anticancer immunologic	Cancer: myeloma, breast
AR54	AltaRex	Murine monoclonal antibody; anticancer immunologic	Cancer: ovarian
IMC-1C11	ImClone Systems	Chimeric monoclonal antibody; anticancer immunologic	Cancer: colorectal
GlioMAb-H	Viventia Biotech	Humanized monoclonal antibody; imaging agent; anticancer immunologic	Diagnosis of cancer; cancer, brain
ING-1	Xoma, Berkeley, CA	Chimeric monoclonal antibody; anticancer immunologic	Cancer: breast, lung (general), ovarian, prostate
Anti-LCG MAbs	eXegenics, Dallas, TX	Monoclonal antibody; anticancer; imaging agent	Cancer: lung, general; diagnosis of cancer
MT-103	Micromet	Murine monoclonal antibody; anticancer immunologic	B-cell lymphoma, non-Hodgkin lymphoma, chronic myelogenous leukemia, acute myelogenous leukemia
KSB-303	KS Biomedix, Guildford, England	Chimeric monoclonal antibody; anticancer immunologic	Diagnosis of cancer; cancer, colorectal
Therex	Antisoma, London, England	Chimeric monoclonal antibody; anticancer immunologic	Cancer: breast
KW-2871	Kyowa Hakko, Tokyo, Japan	Chimeric monoclonal antibody; anticancer immunologic	Melanoma
Anti-HMI.24	Chugai	Chimeric monoclonal antibody; anticancer immunologic	Myeloma
Anti-PTHrP	Chugai	Chimeric monoclonal antibody; anticancer immunologic; osteoporosis	Hypercalcemia of malignancy; cancer, bone
2C4 antibody	Genentech	Chimeric monoclonal antibody; anticancer immunologic	Cancer: breast
SGN-30	Seattle Genetics, Seattle, WA	Monoclonal antibody; anticancer immunologic; multiple sclerosis treatment; immunosuppressant; immunoconjugate	Hodgkin lymphoma
TRAIL-RI MAb, CAT	Cambridge Antibody Technology, Cambridge, England	Humanized monoclonal antibody; anticancer immunologic	Cancer: general
Prostate cancer antibody	Biovation, Aberdeen, Scotland	Monoclonal antibody; anticancer	Cancer: prostate
H22xKi-4	Medarex	Chimeric monoclonal antibody; anticancer immunologic	Hodgkin lymphoma
ABX-MA1	Abgenix	Humanized monoclonal antibody; anticancer immunologic	Melanoma
Imuteran	Nonindustrial source	Monoclonal antibody; anticancer immunologic	Cancer: breast, ovarian
Clinical trial
Monopharm-C	Viventia Biotech	Monoclonal antibody; anticancer immunologic; imaging agent	Cancer: colorectal; diagnosis of cancer

CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; GI, gastrointestinal; VEGF, vascular endothelial growth factor.